Treatment principles for the management of mold infections

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 4, 2015, Pages

  Kontoyiannis, Dimitrios P ^a   Lewis, Russell E ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ARTICLE; DRUG EFFICACY; DRUG USE; EARLY DIAGNOSIS; EMERGENCY CARE; EVIDENCE BASED PRACTICE; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; LONG TERM CARE; NEUROTOXICITY; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMIC MYCOSIS; TREATMENT PLANNING; TREATMENT RESPONSE; ASPERGILLOSIS; DISEASE MANAGEMENT; FUNGUS; MUCORMYCOSIS; PATHOGENICITY;

FUNGI;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; DISEASE MANAGEMENT; FUNGI; HUMANS; IMMUNOCOMPROMISED HOST; MUCORMYCOSIS;

EID: 84926387353     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a019737     Document Type: Article

References (75)

1. Álvarez-Lerma F, Allepuz-Palau A, Gracia MP, Ágeles León M, Navarro A, Sáchez-Ruí H, Iruretagoyena JR, LuqueGóez P. 2008. Impact of intravenous administration of voriconazole in critically ill patients with impaired renal function. J Chemother 1: 93-100.
2. Andes D, Pascual A, Marchetti O. 2008. Antifungal therapeutic drug monitoring: Established and emerging indications. Antimicrob Agents Chemother 53: 24-34.
3. Baddley JW, Andes D., Marr KA, Kontoyiannis DP, Alexander BD, Kauffman CA, Oster RA, Anaissie EJ, Walsh TJ, Schuster MG, et al. 2010. Factors associated with mortality in transplant patients with invasive aspergillosis. Clin Infect Dis 50: 1559-1567.
4. Baxter CG, Marshall A, Roberts M, Felto T, Denning DW. 2011. Peripheral neuropathy in patients on long-term triazole therapy. J Antimicrob Chemother 66: 2136-2139.
5. Ben-Ami R, Halaburda K, Klyasova G, Metan G, Torosian T, Akova M. 2013. A multidisciplinary team approach to the management of patients with suspected or diagnosed invasive fungal disease. J Antimicrob Chemother 68: iii25-iii33.
6. Bowman JC, Hicks PS, Kurtz MB, Rosen H, Schmatz DM, Liberator PA, Douglas CM. 2002. The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob Agents Chemother 46: 3001-3012.
7. Brüggemann RJM, Alffenaar JWC, Blijlevens NMA, Billaud EM, Kosterink JGW, Verweij PE, Burger DM. 2009. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents. Clin Infect Dis 48: 1441-1458.
8. Chai LYA, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, Vonk AG, Maertens J, Lortholary O, Donnelly PJ, Schlamm HT, et al. 2012. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol 50: 2330-2336.
9. Chamilos G, Luna M, Lewis RE, Chemaly R, Kontoyiannis DP. 2007. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: A retrospective, nonrandomized autopsy study. Clin Ther 29: 1980-1986.
10. Chamilos G, Lewis RE, Kontoyiannis DP. 2008. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 47: 503- 509.
11. Clancy CJ, Nguyen MH. 2011. Long-term voriconazole and skin cancer: Is there cause for concern? Curr Infect Dis Rep 13: 536-543.
12. Cojutti P, Candoni A, Simeone E, Franceschi L, Fanin R, Pea F. 2013. Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: Dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations. Antimicrob Agents Chemother 57: 6081-6084.
13. Cordonnier C, Maury S, Pautas C, Bastiè JN, Cheheta S, Castaigne S, Kuentz M, Bretagne S, Ribaud P. 2004. Secondary antifungal prophylaxis with voriconazole to adhere to scheduled treatment in leukemic patients and stem cell transplant recipients. Bone Marrow Transpl 33: 943-948.
14. Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, Pigneux A, Cornely OA, Ullmann AJ, Bofarull RM, et al. 2010. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: Results of the VOSIFI study. Haematologica 95: 1762-1768.
15. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh Y-T, et al. 2007. Posaconazole vs. fluconazole or itraco nazole prophylaxis in patients with neutropenia. N Engl J Med 356: 348-359.
16. Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, Meersseman W, Akova M, Arendrup MC, Arikan-Akdagli S, et al. 2012. ESCMID guideline for the diagnosis and management of Candida diseases 2012: Non-neutropenic adult patients. Clin Microbiol Infect 18: 19-37.
17. Denning DW, Bowyer P. 2013. Voriconazole resistance in Aspergillus fumigatus: Should we be concerned? Clin Infect Dis 57: 521-523.
18. de Pauw BE. 2005. Between over- and undertreatment of invasive fungal disease. Clin Infect Dis 41: 1251-1253.
19. de Pauw E, Viscoli C. 2011. Managing invasive fungal infections: Relying on clinical instincts or on a rational navigation system? J Antimicrob Chemother 66: S1:i55-i58.
20. Dodds-Ashley E. 2010. Management of drug and food interactions with azole antifungal agents in transplant recipients. Pharmacotherapy 30: 842-854.
21. Dolton MJ, Ray JE, Marriott D, McLachlan AJ. 2012. Posaconazole exposure-response relationship: Evaluating the utility of therapeutic drug monitoring. Antimicrob Agents Chemother 56: 2806-2813.
22. Drgona L, Colita A, Klimko N, Rahav G, Ozcan MA, Donnelly JP. 2013a. Triggers for driving treatment of at-risk patients with invasive fungal disease. J Antimicrob Chemother 68: iii17-iii24.
23. Drgona L, Khachatryan A, Stephens J, Charbonneau C, Kantecki M, Haider S, Barnes R. 2013b. Clinical and economic burden of invasive fungal diseases in Europe: Focus on pre-emptive and empirical treatment of Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis 1-15.
24. Eschenauer G, DePestel DD. 2007. Comparison of echinocandin antifungals. Ther Clin Risk Manag 3: 71-97.
25. Espinel-Ingroff A. 2001. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi. J Clin Microbiol 39: 954-958.
26. Even C, Bastuji-Garin S, Hicheri Y, Tulkins P, Botterel F, Maury S, Cabanne L, Bretagne S, Cordonnier C. 2011. Impact of invasive fungal disease on the chemotherapy schedule and event-free survival in acute leukemia patients who survived fungal disease: A case-control study. Haematologica 96: 337-341.
27. Falci DR, Pasqualotto AC. 2013. Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections. Infect Drug Resist 6: 163-174.
28. Freemantle N, Tharmanathan P, Herbrecht R. 2011. Systematic review and mixed treatment comparison of randomized evidence for empirical, pre-emptive and directed treatment strategies for invasive mould disease. J Antimicrob Chemother 66: i25-i35.
29. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Rolston KV, Young J-AH, Wingard JR, et al. 2011. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 52: e56-e93.
30. Fung S-L, Chau C-H, Yew W-W. 2008. Cardiovascular adverse effects during itraconazole therapy. Eur Respir J 32: 240.
31. Gauthier GM, Nork TM, Prince R, Andes D. 2005. Subtherapeutic ocular penetration of caspofungin and associated treatment failure in Candida albicans endophthalmitis. Clin Infect Dis 41: e27-e28.
32. Greene RE, Schlamm HT, Oestmann J-W, Stark P, Durand C, Lortholary O, Wingard JR, Herbrecht R, Ribaud P, Patterson TF, et al. 2007. Imaging findings in acute invasive pulmonary aspergillosis: Clinical significance of the halo sign. Clin Infect Dis 44: 373-379.
33. Hafner V, Czock D, Burhenne J, Riedel KD, Bommer J, Mikus G, Machleidt C, Weinreich T, Haefeli WE. 2010. Pharmacokinetics of sulfobutylether-b-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrob Agents Chemother 54: 2596-2602.
34. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann J-W, Kern WV, Marr KA, Ribaud P, Lortholary O, et al. 2002. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347: 408-415.
35. Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, Schwartz S, Ullmann AJ, Meert L, Paesmans M, et al. 2010. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: A European organisation for research and treatment of cancer study. Bone Marrow Transplant 45: 1227-1233.
36. Herbrecht R, Bories P, Moulin J-C, Ledoux M-P, Letscher Bru V. 2012. Risk stratification for invasive aspergillosis in immunocompromised patients. Ann NY Acad Sci 1272: 23-30.
37. Hoenigl M, Duettmann W, Raggam RB, Seeber K, Troppan K, Fruhwald S, Prueller F, Wagner J, Valentin T, ZollnerSchwetz I, et al. 2013. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother 57: 3262-3267.
38. Hope WW, Petraitis V, Petraitiene R, Aghamolla T, Bacher J, Walsh TJ. 2010. The initial 96 hours of invasive pulmonary aspergillosis: Histopathology, comparative kinetics of galactomannan and (1!3)-b-D-glucan, and consequences of delayed antifungal therapy. Antimicrob Agents Chemother 54: 4879-4886.
39. Kohl V, Muller C, Cornely OA, Abduljalil K, Fuhr U, Vehreschild JJ, Scheid C, Hallek M, Ruping MJGT. 2009. Factors influencing pharmacokinetics of prophylactic posaconazole in patients undergoing allogeneic stem cell transplantation. Antimicrob Agents Chemother 54: 207-212.
40. Kontoyiannis DP, Lewis RE. 2011. How I treat mucormycosis. Blood 118: 1216-1224.
41. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, et al. 2005. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. J Infect Dis 191: 1350-1360.
42. Krishna G, Ma L, Martinho M, Preston RA, O’Mara E. 2012. A new solid oral tablet formulation of posaconazole: A randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers. J Antimicrob Chemother 67: 2725-2730.
43. Lee SH, Kim BH, Nam WS, Yoon SH. 2012. Effect of CYP2C19 polymorphism on the pharmacokinetics of voriconazole after single and multiple doses in healthy volunteers. J Clin Pharmacol 52: 195-203.
44. Lehrnbecher T, Bochennek K, Schrey D, Groll AH. 2011. Antifungal therapy in pediatric patients. Curr Fungal Infect Rep 5: 103-110.
45. Leventakos K, Lewis RE, Kontoyiannis DP. 2010. Fungal infections in leukemia patients: How do we prevent and treat them? Clin Infect Dis 50: 405-415.
46. Lewis RE, Wiederhold NP, Klepser ME. 2005. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrob Agents Chemother 49: 945-951.
47. Maertens J, Groll AH, Cordonnier C, la Cámara de R, Roilides E, Marchetti O. 2011. Treatment and timing in invasive mould disease. J Antimicrob Chemother 66: S1:i37-i43.
48. Marr KA, Laverdiere M, Gugel A, Leisenring W. 2005. Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay. Clin Infect Dis 40: 1762-1769.
49. Marr KA, Schlamm H, Rottinghaus ST, Jagannatha S, Bow EJ, Wingard JR, Pappas P, Herbrecht R, Walsh TJ, Maertens J, et al. 2012. A randomized, double-blind study of combination antifungal therapy with voriconazole and anidulafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Abstract LB-2812. London, March 31-April 3.
50. Nagappan V, Deresinski S. 2007. Posaconazole: A broadspectrum triazole antifungal agent. Clin Infect Dis 45: 1610-1617.
51. Norkin M, Wingard JR. 2013. Diagnostic strategies for invasive fungal infections in patients with hematologic malignancies and hematopoietic stem cell transplant recipients. J Nat Compr Cancer Netw 11: 941-949.
52. Pagano L, Akova M, Dimopoulos G, Herbrecht R, Drgona L, Blijlevens N. 2010. Risk assessment and prognostic factors for mould-related diseases in immunocompromised patients. J Antimicrob Chemother 66: 5-114.
53. Pai MP, Bearden DT. 2007. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 27: 1081-1091.
54. Pai MP, Lodise TP. 2011. Steady-state plasma pharmacokinetics of oral voriconazole in obese adults. Antimicrob Agents Chemother 55: 2601-2605.
55. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46: 201-211.
56. Pascual A, Csajka C, Buclin T, Bolay S, Bille J, Calandra T, Marchetti O. 2012. Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: Population pharmacokinetics-based analysis of adult patients with invasive fungal infections. Clin Infect Dis 55: 381-390.
57. Pfaller MA, Diekema DJ. 2010. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 36: 1-53.
58. Pfaller M, Boyken L, Hollis R, Kroeger J, Messer S, Tendolkar S, Diekema D. 2011. Use of epidemiological cutoff values to examine 9-year trends in susceptibility of Aspergillus species to the triazoles. J Clin Microbiol 49: 586-590.
59. Rex JH, Eisenstein BI, Alder J, Goldberger M, Meyer R, Dane A, Friedland I, Knirsch C, Sanhai WR, Tomayko J, et al. 2013. A comprehensive regulatory framework to address the unmet need for new antibacterial treatments. Lancet Infect Dis 13: 269-275.
60. Rogers PD, Jenkins JK, Chapman SW, Ndebele K, Chapman BA, Cleary JD. 1998. Amphotericin B activation of human genes encoding for cytokines. J Infect Dis 178: 1726- 1733.
61. Saliba F, Dupont B. 2008. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. Med Mycol 46: 97-112.
62. Sing N, Perfect JR. 2007. Immune reconstitution syndrome associated with opportunistic mycoses. Lancet Infect Dis 7: 395-401.
63. Sipsas NV, Kontoyiannis DP. 2006. Clinical issues regarding relapsing aspergillosis and the efficacy of secondary antifungal prophylaxis in patients. Clin Infect Dis 42: 1584- 91.
64. Skiada A, Lanternier F, Groll AH, Pagano L, Zimmerli S, Herbrecht R, Lortholary O, Petrikkos GL. 2012. Diagnosis and treatment of mucormycosis in patients with haematological malignancies: Guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 98: 492-504.
65. Song JC, Deresinski S. 2005. Hepatotoxicity of antifungal agents. Curr Opin Invest Drugs 6: 170-177.
66. Spellberg B, Rieg G, Bayer A, Edwards JE Jr. 2003. Lack of cross-hepatotoxicity between fluconazole and voriconazole. Clin Infect Dis 36: 1091-1093.
67. Spreghini E, Orlando F, Giannini D, Barchiesi F. 2010. In vitro and in vivo activities of posaconazole against zygomycetes with various degrees of susceptibility. J Antimicrob Chemother 65: 2158-2163.
68. Tong KB, Lau CJ, Murtagh K, Layton AJ. 2009. The economic impact of aspergillosis: Analysis of hospital expenditures across patient subgroups. Intern J Infect Dis 13: 24- 36.
69. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, et al. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356: 335-347.
70. Vaes M, Hites M, Cotton F, Bourguignon AM, Csergo M, Rasson C, Ameye L, Bron D, Jacobs F, Aoun M. 2012. Therapeutic drug monitoring of posaconazole in patients with acute myeloid leukemia or Myelodysplastic syndrome. Antimicrob Agents Chemother 56: 6298-6303.
71. Verweij PE, Mellado E, Melchers WJG. 2007. Multiple-triazole-resistant aspergillosis. N Engl J Med 356: 1481- 1483.
72. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA, et al. 2008. Treatment of aspergil losis: Clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46: 327-360.
73. Wang JL, Chang CH, Young-Xu Y, Chan KA. 2010. Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Antimicrob Agents Chemother 54: 2409-2419.
74. Wermers RA, Cooper K, Razonable RR, Deziel PJ, Whitford GM, Kremers WK, Moyer TP. 2011. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin Infect Dis 52: 604-611.
75. Whitney LC, Bicanic T. 2015. Treatment principles for Candida and Cryptococcus. Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a024158.